Search results for " CIRROSI"

showing 9 items of 9 documents

Overcoming a “Probable” Diagnosis in Antimitochondrial Antibody Negative Primary Biliary Cirrhosis: Study of 100 Sera and Review of the Literature

2010

Serum anti-mitochondrial antibodies (AMA) are the serological hallmark of primary biliary cirrhosis (PBC), yet up to 15% of PBC sera are AMA negative at routine indirect immunofluorescence (IIF) while being referred to as “probable” cases. The diagnostic role of PBC-specific antinuclear antibodies (ANA) remains to be determined. We will report herein data on the accuracy of new laboratory tools for AMA and PBC-specific ANA in a large series of PBC sera that were AMA-negative at IIF. We will also provide a discussion of the history and current status of AMA detection methods. We included IIF AMA-negative PBC sera (n = 100) and sera from patients with other chronic liver diseases (n = 104) th…

AdultMaleAnti-nuclear antibodyNuclear dotsPBCSerologyAnticorpo antimitocondrio cirrosi biliare primitivaPrimary biliary cirrhosisAntigenparasitic diseasesHumansImmunology and AllergyMedicineskin and connective tissue diseasesAgedAutoantibodiesAged 80 and overbiologyLiver Cirrhosis Biliarybusiness.industryAutoantibodyIIfGeneral MedicineMiddle Agedmedicine.diseasedigestive system diseasesMitochondriaImmunologybiology.proteinFemaleAntibodybusinessClinical Reviews in Allergy & Immunology
researchProduct

Ruolo dei pattern ecografici nella sorveglianza per la diagnosi precoce dell'HCC

EcografiacirrosiEcografia; epatocarcinoma; sorveglianza; cirrosisorveglianzaepatocarcinoma
researchProduct

SCREENING DELL’EPATOCARCINOMA (HCC) NELLA CIRROSI EPATICA (CE): RUOLO DEI PATTERN ECOGRAFICI (US)

2013

Epatocarcinoma ecografia cirrosi epatica sorveglianza
researchProduct

Significato clinico di polimorfismi di geni citochinici (IL-6, TNF-ALPHA) nella cirrosi epatica e nel carcinoma epatocellulare

2009

HCC cirrosi epatica polimorfismi citochine IL-6 TFN-ALPHA
researchProduct

Heart rate variability is associated with disease severity and portal hypertension in cirrhosis

2023

Introduction: Autonomic nervous system activity in cirrhotic portal hypertension is linked to hyperdynamic circulation. Heart rate variability (HRV) is a validated noninvasive method to assess the sympathovagal balance. To investigate the correlation between HRV parameters and degree of portal hypertension, we studied a cohort of patients with cirrhosis accounting for etiology and treatments. Patients and Methods: In this cross-sectional, observational cohort study, 157 outpatients of both sex with nonalcoholic cirrhosis were assessed by upper gastrointestinal endoscopy to search for esophagogastric varices. Twenty-four-hour electrocardiogram Holter monitoring with 3 HRV parameters measurem…

Hepatologyportal hypertension cirrosi heart rate variability liver decompensationHepatology Communications
researchProduct

POLIMORFISMI A SINGOLO NUCLEOTIDE ( SINGLE NUCLEOTIDE POLYMORPHISMS, SNPs) COME POSSIBILI MARCATORI GENETICI PER LA VALUTAZIONE DEL RISCHIO DI SVILUP…

Settore MED/09 - Medicina InternaCIRROSIPOLIMORFISMIEPATOCARCINOMAPOLIMORFISMI; CIRROSI; EPATOCARCINOMA;
researchProduct

EFFETTI DELLA TERAPIA CON DIRECT ACTING ANTIVIRALS (DAAS) SUI PARAMETRI ECOGRAFICI DI IPERTENSIONE PORTALE

2017

Obiettivi dello studio: Tra gli end point della terapia antivirale con DAAs nella cirrosi HCV (LCHCV) oltre all' eradicazione del virus vi sono: la regressione della fibrosi e dell’ipertensione portale. Abbiamo valutato in pazienti LCHCV e risposta sostenuta (SVR) alla terapia con DAAs il comportamento dell’AST to Platelet Ratio Index (APRI) (marker indiretto di fibrosi) e di due segni ecografici di ipertensione portale: calibro della vena porta (cVP) e diametro longitudinale della milza (DLM). Materiali: 98 pazienti con LCHCV,al Baseline (BL) a fine terapia (FT) e tre mesi (PostT3) e 9 mesi dopo la fine della terapia (PostT9) eseguivano i test di funzionalità epatica e la conta piastrinica…

Settore MED/09 - Medicina InternaDIRECT ACTING ANTIVIRALS EPATITI CRONICHE CIRROSI IPERTENSIONE PORTALE ECOGRAFIADIRECT ACTING ANTIVIRALSChronic hepatitis Liver Cirrhosis Portal Hypertension Ultrasound
researchProduct

Multimodal approaches to the treatment of hepatocellular carcinoma.

2008

The prevalence of hepatocellular carcinoma in Europe and the US is increasing and is currently the leading cause of death in patients with cirrhosis. Surveillance programs for patients with cirrhosis aim to detect tumors at an early stage, when the greatest therapeutic benefits can be achieved. Curative treatments for early-stage tumors include liver transplantation, resection and percutaneous ablation. Transarterial chemoembolization (TACE) and sorafenib can improve survival for patients with intermediate and advanced tumors, respectively. In clinical practice, combination therapies are often used, despite limited evidence to support this approach from randomized controlled trials. Combina…

SorafenibNiacinamidemedicine.medical_specialtyCarcinoma HepatocellularCombination therapyWaiting ListsRadiofrequency ablationPyridinesmedicine.medical_treatmentSalvage therapyAntineoplastic AgentsLiver transplantationlaw.inventionInjectionslawPreoperative CaremedicineCombined Modality TherapyHumansChemoembolization TherapeuticSalvage TherapyHepatologyEthanolbusiness.industryepatocarcinoma cirrosi HBV HCVPhenylurea CompoundsBenzenesulfonatesLiver NeoplasmsGastroenterologySorafenibmedicine.diseaseCombined Modality TherapyEmbolization TherapeuticSurgeryLiver TransplantationHepatocellular carcinomaCatheter AblationRadiotherapy AdjuvantRadiologyPercutaneous ethanol injectionbusinessmedicine.drugNature clinical practice. Gastroenterologyhepatology
researchProduct

Encefalopatia iponatriemica in peritonite batterica spontanea in soggetto con cirrosi epatica scompensata.

2008

encefalopatia iponatriemia peritonite batterica spontanea cirrosi epatica
researchProduct